Cocrystal Pharma (COCP) said Tuesday it plans to extend enrollment in a phase 2a influenza challenge study due to low influenza infection among study participants, making virology results uninterpretable.
The study evaluating Cocrystal's investigational inhibitor CC-42344 has shown no serious adverse events so far, the company said.
Cocrystal Pharma shares were down 32% in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。